Abstract 199P
Background
In literature some studies suggested that in patients having solid malignancies poor prognosis is associated with vitamin D3 deficiency and replacement of vitamin D3 might have positive impact on prognosis. However, some of the results of the studies were against this suggestion. Therefore, in the current study we aimed to compare the clinical, pathological features and survival rates in patients with early breast cancer having regular vitamin D3 replacement or not.
Methods
In between October 2002 and October 2015, patients with early stage breast cancer were included in study population. The patients were divided into two groups according to their regular vitamin D3 replacement status. Vitamin D3 doses that the patients were receiving were calculated to increase the levels beyond 20 ng/mL (50 nmol/L). The patients with metastasis/relapse or second primary cancers were excluded.
Results
In vitamin D3 and non-vitamin D3 group 92 and 2864 patients were included. Median follow up time was 60 (min:1- max:420) months. Mean age at time of diagnosis, rate of patients with postmenopause, T1 tumor and breast conserving surgery was significantly higher in vitamin D3 replacement group compared with non-vitamin D3 group (p
Conclusions
Regular vitamin D3 replacement therapy did not have effect on prognosis of patients with early breast cancer. Most of the postmenopausal and older aged patients with early breast cancer received vitamin D3 replacement most probably due to higher rate of osteoporosis in this aged patient group.
Clinical and pathological features of early breast cancer patients in vitamin D and non-vitamin D group
| Regular Vitamin D Replacement Group (n = 92) (%) | Non-Vitamin D Group (n = 2864) (%) | p | |
|---|---|---|---|
| Mean Age | 59 ± 11 | 49 ± 13 | 0.001 |
| Invasive Histopathological Subtype Dutal Lobular Other | 75 5.4 19.6 | 70 5 25 | 0.77 |
| Grade 1 2 3 | 21 45.2 33.9 | 13 44.9 42.1 | 0.14 |
| Body Mass Index 0-25 kg/m2 25-29.9 kg/m2 ≥30 kg/m2 | 34.7 37.3 28 | 35.4 36.6 28.1 | 0.98 |
| Menapausal Status Premenopausal Perimenopausal Postmenopausal | 22.8 8.7 68.5 | 49.8 7.1 43.1 | 0.001 |
| Breast Surgery Mastectomy Breast Conserving | 52.2 46.4 | 65.7 33.8 | 0.04 |
| Estrogen Receptor Positive Negative | 83.3 16.7 | 75.2 24.8 | 0.11 |
| Progesterone Receptor Positive Negative | 77.8 22.2 | 71.4 28.6 | 0.23 |
| Her-2 Status Positive Negative | 13.3 86.7 | 19.4 80.6 | 0.18 |
| TNM Tumor Stage T1 T2 T3 T4 | 55.6 31.9 9.7 2.8 | 34.8 48.8 13.6 2.8 | 0.004 |
| TNM Nodal Stage N0 N1 N2 N3 | 54.1 29.7 8.1 5.4 | 46 27.3 12.5 9.5 | 0.37 |
Clinical trial identification
None
Legal entity responsible for the study
Ankara Numune Education and Research Hospital
Funding
None
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract